Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoma, Mantle-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Paraproteinemias 1Lymphoproliferative Disorders 1Hemostatic Disorders 1Hematologic Diseases 1

Interventions

Bortezomib 6Dexamethasone 5filanesib 2dacetuzumab 2Steroids 2Lenalidomide 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Cyclophosphamide 2Clinical Protocols 2ficlatuzumab 1epratuzumab 1birtamimab 1Zoledronic Acid 1Vorinostat 1Proteasome Inhibitors 1Plasma Exchange 1KW-2478 1Hsp90 inhibitor KU757 1Erlotinib Hydrochloride 1Denosumab 1Calcium Dobesilate 1CLR1404 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Paraproteinemias × epratuzumab × Clear all
NCT00113802 2021-08-19

Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia

Gilead Sciences

Phase 2 Terminated
31 enrolled
Lymphoid

Hematologic Diseases, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Paraproteinemias, Hemostatic Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡